Symphogen raises 100 million euros and buys development time for cancer portfolio
This article was originally published in Scrip
Symphogen has raised 100 million euros(131 million dollars), the largest ever financing for a private European biotech company, buying it time to complete several Phase IIa oncology trials before any future return to private investors or the public market for more funds. The Danish company is developing antibody and antibody combination therapeutics (monoclonals, monoclonal mixtures and polyclonals) to treat cancer, infectious and autoimmune diseases.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.